Showing results (1701-1710 of 2,755) with videos related to
Sort By:
Pageof 276
Pharmacogenomics|October 27, 2011
Additive effect of GHRd3 and COLIA1 polymorphisms on the GH-substitution dose in GH-deficient adultsSilke Hartleb, Ursula Plöckinger, Günter K Stalla, et al.Pharmacogenomics|October 20, 2011
Pharmacogenomic characterization of US FDA-approved cytotoxic drugsEric J Peters, Alison Motsinger-Reif, Tammy M Havener, et al.Pharmacogenomics|October 20, 2011
Pharmacogenomics and epilepsy: the road aheadGianpiero L Cavalleri, Mark McCormack, Saud Alhusaini, et al.Pharmacogenomics|October 20, 2011
Effect of genetic polymorphisms in the folate pathway on methotrexate therapy in rheumatic diseasesLisa K Stamp, Rebecca L RobertsPharmacogenomics|October 20, 2011
The effect of ABCB1 genetic variants on chemotherapy response in HIV and cancer treatmentKerry Reed, Amadeo M ParissentiPharmacogenomics|September 10, 2011
Impact of genetic polymorphisms in ABCB1, CYP2B6, OPRM1, ANKK1 and DRD2 genes on methadone therapy in Han Chinese patientsChin-Chuan Hung, Mu-Han Chiou, Bo-Hau Huang, et al.Pharmacogenomics|September 10, 2011
Genetic polymorphisms in CYP3A4 are associated with withdrawal symptoms and adverse reactions in methadone maintenance patientsChia-Hui Chen, Sheng-Chang Wang, Hsiao-Hui Tsou, et al.Pharmacogenomics|September 17, 2011
Four decades of modern pharmacogenomics: from promise to clinical utility. World PGX Summit 2011. Boston, USA, 26-27 April, 2011Peter Ma GroenenPharmacogenomics|September 17, 2011
The association of polymorphisms in 5-fluorouracil metabolism genes with outcome in adjuvant treatment of colorectal cancerShoaib Afzal, Milena Gusella, Søren Astrup Jensen, et al.Pharmacogenomics|September 17, 2011
Dihydropyrimidine dehydrogenase gene as a major predictor of severe 5-fluorouracil toxicityUrsula Amstutz, Tanja K Froehlich, Carlo R LargiadèrPageof 276